SEC Form 4 · accession 0000880771-16-000175
SCICLONE PHARMACEUTICALS INC · SCLN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert King
Officer — SVP of Prod. Dev/Supply Chain
Period of report
Aug 12, 2016
Accepted (ET)
Aug 16, 2016 · 5:28 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000880771
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 12, 2016 | M | 46,667 | $4.52 | A | 63,511 | D | |
| Common Stock | Aug 12, 2016 | S | 46,667 | $10.41 | D | 16,844 | D | |
| Common Stock | Aug 12, 2016 | M | 2,000 | $0.00 | A | 18,844 | D | |
| Common Stock | Aug 12, 2016 | S | 2,000 | $10.41 | D | 16,844 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Options (right to buy)F2,F3 | $4.52 | Aug 12, 2016 | M | 46,667 | D | — | Mar 14, 2024 | Common Stock | 46,667 | 33,333 | D |
| Restricted Stock UnitF2,F4,F5 | — | Aug 12, 2016 | M | 2,000 | A | — | — | Common Stock | 2,000 | 13,000 | D |
Explanation of responses
- F1Includes 4,262 shares purchased under the Issuer's Employee Stock Purchase Plan from February 28, 2015 through May 31, 2016.
- F2Granted under the Issuer's 2005 Equity Incentive Plan.
- F325% of such shares vest from one year from the date of grant and 2.0833% vests each month thereafter, provided that the Reporting Person continues to be employed by the Issuer.
- F4Each restricted stock unit represents the contingent right to receive one share of SciClone Pharmaceuticals, Inc.'s common stock.
- F5Vesting for such RSUs will occur 25% on March 16, 2016, 25% on March 16, 2017, 25% on March 16, 2018, and 25% on March 16, 2019, or on such later date thereafter as the Company's trading window opens, if it is not open on any of such dates, contingent upon the executive's continued employment.